AI Article Synopsis
- MTCA-KKV is a nano-medicine designed to adhere to activated platelets and specifically target P-selectin and GPIIb/IIIa to treat blood clots.
- The nano-medicine was evaluated for its characteristics, anti-thrombotic and thrombolytic activities, and ability to target and release medical agents effectively.
- In vivo studies showed that MTCA-KKV formed nanoparticles under 100 nm, successfully targeted blood clots, released therapeutic agents to prevent and dissolve thrombosis, indicating its potential as an effective treatment for clot-related conditions.
Article Abstract
Background: In vitro (1R,3S)-1-methyl-1,2,3,4-tetrahydro-β-carboline-3-carboxyl-Lys(Pro-Ala-Lys)-Arg-Gly-Asp-Val (MTCA-KKV) adheres activated platelets, targets P-selectin and GPIIb/IIIa. This led to the development of MTCA-KKV as thrombus targeting nano-medicine.
Methods: MTCA-KKV was characterized by nano-feature, anti-thrombotic activity, thrombolytic activity, thrombus target and targeting release.
Results: In vivo 0.01 μmol/kg of MTCA-KKV formed nano-particles less than 100 nm in diameter, targeted thrombus, released anti-thrombotic and thrombolytic pharmacophores, prevented thrombosis and dissolved blood clots.
Conclusion: Based on the profiles of targeting thrombus, targeting release, inhibiting thrombosis and dissolving blood clots MTCA-KKV is a promising nano-medicine.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6614858 | PMC |
| http://dx.doi.org/10.2147/IJN.S206294 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The transition of the criteria for disseminated intravascular coagulation and the targeted patients in randomized controlled trials over the decades: a scoping review.
Thromb J
December 2024
Department of Emergency and Critical Care Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, 160-8582, Tokyo, Japan.
Background: Disseminated intravascular coagulation (DIC) is a severe complication in septic patients. The Japanese Ministry of Health and Welfare (JMHW)-DIC criteria, the first DIC criteria, were established in 1983, and several other criteria have been proposed since then, including the International Society on Thrombosis and Haemostasis (ISTH)-overt DIC criteria and the Japanese Association for Acute Medicine (JAAM) DIC criteria. This study aimed to look into the transition of DIC criteria used in randomized controlled trials (RCTs) for sepsis-induced DIC.
View Article and Find Full Text PDFObjective: Aim: To summarise what is known about the inflammatory nature of atherosclerosis to date.
Patients And Methods: Materials and Methods: We conducted the search using Google Scholar and Medline and selected state-of-the-art articles that were consistent with the aim of study.
Conclusion: Conclusions: To date, there is sufficient evidence that atherosclerosis is driven by the inflammatory process.
Platelet-derived biomaterials for targeted drug delivery and tissue repair.
J Mater Chem B
December 2024
College of Biomedical Engineering, National Engineering Research Centre for Biomaterials, Sichuan University, Chengdu, Sichuan 610064, China.
Platelets are nucleic-free cells with a lifespan of 7-10 days in the bloodstream, playing a crucial role in various physiological processes such as hemostasis, thrombus formation, tumor development and metastasis, inflammation, and host defense. By utilizing the unique structural and functional characteristics of platelets, platelet-modified nano-drugs can evade immune recognition and clearance and facilitate prolonged circulation , which ultimately allows the nanoparticles to reach sites of disease such as thrombi, tumors, inflammation, or bacterial infections, leading to specific adhesion and significantly enhancing the efficiency of targeted drug delivery. This paper reviews the novel design and application of platelet-derived biomaterials in various diseases in recent years and comprehensively demonstrates the potential of platelet-derived biomaterials in the fields of disease therapy and biodefence, which will provide a reference for advancing the development of platelet-derived biomaterials and clinical practice.
View Article and Find Full Text PDFProgrammable ultrasound-mediated swarms manipulation of bacteria-red blood cell microrobots for tumor-specific thrombosis and robust photothermal therapy.
Trends Biotechnol
December 2024
Guangdong Key Laboratory of Nanomedicine, CAS-HK Joint Lab of Biomaterials, Shenzhen Institute of Advanced Technology (SIAT), Chinese Academy of Sciences, Shenzhen 518055, PR China; Sino-Euro Center of Biomedicine and Health, Shenzhen 518024, PR China. Electronic address:
Despite the excellent advantages of biomicrorobots, such as autonomous navigation and targeting actuation, effective penetration and retention to deep lesion sites for effective therapy remains a longstanding challenge. Here, we present dual-engine cell microrobots, which we refer to as PR-robots, created by conjugating photosynthetic bacteria (PSB) with red blood cells (RBCs). The robots penetrate the tumor interior in swarms through combined hypoxic traction and ultrasound actuation (UA).
View Article and Find Full Text PDFDiscovery and biological evaluation of potent 2-trifluoromethyl acrylamide warhead-containing inhibitors of protein disulfide isomerase.
Eur J Med Chem
December 2024
Ph.D. Program in Drug Discovery and Development Industry, College of Pharmacy, Taipei Medical University, Taipei, Taiwan; School of Pharmacy, Taipei Medical University, Taipei, Taiwan. Electronic address:
Protein disulfide isomerase (PDI) regulates multiple protein functions by catalyzing the oxidation, reduction, and isomerization of disulfide bonds. The enzyme is considered a potential target for treating thrombosis. We previously developed a potent PDI inhibitor, CPD, which contains the propiolamide as a warhead targeting cysteine residue in PDI.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!